Neurocrine’s Bad Dream Continues: Indiplon FDA Approval Requires Three More Studies
This article was originally published in The Pink Sheet Daily
FDA “approvable” letter for the insomnia agent is particularly stinging because Neurocrine was set to announce a new commercialization agreement with a leading pharma company.
You may also be interested in...
Sleep aid could at last reach market late in 2008.
Lilly, which markets injectable exenatide, may inherit commercialization rights to the nasal spray formulation if Nastech/Amylin’s development proves successful.
Neurocrine will meet with FDA within 10 days to discuss the “approvable” and “not approvable” letters for the insomnia product.